Rienso (ferumoxytol) withdrawn

Iron deficiency is common in the later stages of CKD as a result of decreased renal synthesis of erythropoieses | SCIENCE PHOTO LIBRARY
Iron deficiency is common in the later stages of CKD as a result of decreased renal synthesis of erythropoieses | SCIENCE PHOTO LIBRARY

The intravenous iron preparation Rienso (ferumoxytol) has been withdrawn for commercial reasons. Launched in 2012, it was licensed for the treatment of iron deficiency anaemia in patients with chronic kidney disease.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

A woman wearing a white vest as a blue-gloved hand of a healthcare professional are seen injecting a vaccine.

'Nocebo' effect may cause two-thirds of COVID-19 vaccine reactions, study suggests

Two-thirds of adverse reactions reported with the COVID-19...

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...